Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

Öz

Anahtar Kelimeler

• JAK2V617F mutasyonu, BCR/ABL translokasyonu, miyeloproliferatif bozukluklar, miyelofibroz

Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

Abstract

liland DG. Expression of Jak2V617F causes a polycthemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–81. 4. Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Phil- adelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3

Keywords

• JAK2V617F mutation, BCR/ABL translocation, miyeloproliferative disorders, myelofibrosis

Kaynakça

1. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006;240–5.
2. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.
3. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycthemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–81.
4. Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3.
5. Bock O, Büsche G, Koop C, Schröter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the JH2 pseudokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. Journal of Molecular Diagnostics 2006; 8:170-7.
6. Krämer A. JAK2-V617F and BCR-ABL-double Jeopardy? Leukemia Res 2008;32:1489–90.
7. Pardini S, Fozza C, Contini S et al. A case of coexistence between JAK2V617F and BCR/ABL. Eur J Hematol 2008; 81.75–6.
8. Inami M, Inokuchi K, Okabe M et al. Polycthemia associated with the JAK2V617F mutation emerged during treatment of chronic mylogeneous leukemia. Leukemia 2007;21:1103–4.

9. Cambier N, Renneville A, Cazaentre T et al. JAK2V617Fpositive polycythemia vera and philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008;22:1454–5.
10. Hussein K, Bock O, Seegers E et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disorder with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106–7.
11. Krämer A, Reiter A, Kruth J et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia. Lancet 2007;8:658–60.
12. Veronese L, Tchirkov A, Richard-Pebrel C et al. A thrombocytosis occuring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm. Leuk Res 2010;34:94–6.
13. Campiotti L, Appio L, Solbiati F, AgenoW, Venco A. JAK2V617F mutation and Philadelphia positive chronic myeloid leukemia. Leukemia Research 2009; 33.212–3.
14. Jallades L, Hateyye S, Tigaud I et al. Emergence of therapy-unrelated CML on a backgraund of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008;32:1608–10.
15. Bornhäuser M, Mohr B, Oelschlaegel U et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21:1824–6.
16. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005;128:730–6.